U-Neuron Biomedical

U-Neuron Biomedical EBITDA per Employee

EBITDA per Employee of U-Neuron Biomedical (6973.TWO) as of Oct 17, 2026.

EBITDA per Employee

-TWD

Last updated:

EBITDA per Employee of U-Neuron Biomedical is 2026 - TWD. EBITDA per Employee of U-Neuron Biomedical was 2025 - TWD. It decreases by % lower compared to the previous year.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

U-Neuron Biomedical Stock analysis

What does U-Neuron Biomedical do? U-Neuron Biomedical Inc, headquartered in Taipei, Taiwan, operates in the Health Care sector within the Biotechnology industry. The company, listed on 20 July 2023, develops cosmetics, health care consumer products, and new drugs. Its drug development focuses on allogeneic amniotic fluid stem cells for applications like erectile dysfunction (UA002) and dry eye (UB003). Cosmetic products, featuring deer amniotic fluid stem cell derivatives, include anti-aging masks, essences, and creams for repair and hydration, primarily sold domestically in Taiwan. U-Neuron Biomedical is one of the most popular companies on Eulerpool.

Frequently Asked Questions about U-Neuron Biomedical stock

On Eulerpool you can find the complete historical development of EBITDA per Employee U-Neuron Biomedical since 2006 – with annual values, charts, and detailed analysis.

EBITDA per employee measures operating cash earnings generated per employee, showing workforce productivity before depreciation and financing effects.

EBITDA per Employee's TWD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA per Employee's U-Neuron Biomedical historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — U-Neuron Biomedical

All Key Metrics — U-Neuron Biomedical